Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Semler Scientific, Inc. shareholder Weiss Asset Management LP reported beneficial ownership of 801,086 shares of common stock, representing 5.2% of the class. This percentage is based on 15,285,092 shares outstanding as of November 19, 2025, as reported in the issuer’s Schedule 14A.
Weiss Asset Management, GP LLC, and Andrew M. Weiss report shared voting and dispositive power over 801,086 shares, with no sole voting or dispositive power. They state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Semler Scientific.
Semler Scientific, Inc. reports that it has been acquired by Strive, Inc., with Semler becoming a wholly owned subsidiary through a completed merger. Each share of Semler common stock outstanding immediately before the merger was converted into the right to receive 21.05 shares of Strive Class A common stock, with cash paid instead of fractional shares. Semler’s $100 million 4.25% Convertible Senior Notes due August 1, 2030 now convert into Strive Class A common stock under a supplemental indenture, with an initial adjusted conversion rate of 275.3887 shares per $1,000 principal amount and an initial maximum conversion rate of 344.2348 shares, making 34,423,480 Strive shares initially issuable. Strive guarantees the notes, which remain senior unsecured obligations of Semler. Semler terminated its at-the-market equity Sales Agreement and plans to delist its common stock from Nasdaq and deregister it, following a change in control and replacement of the prior board and officers with Strive designees.
Semler Scientific director Eric Semler reported the automatic disposition of his Semler Scientific common stock and stock options due to the completion of the merger with Strive, Inc. On January 16, 2026, Merger Sub merged into Semler Scientific, which became a wholly owned subsidiary of Strive.
Each share of Semler Scientific common stock outstanding immediately before the effective time was converted into the right to receive 21.05 shares of Strive Class A common stock, plus cash instead of fractional Strive shares, under the Merger Agreement. The filing shows 636,346 shares of common stock held directly and 77,771 shares held indirectly through TCS Capital Advisors, LLC, all disposed of in this conversion.
Each outstanding Semler Scientific stock option, whether vested or unvested, was converted at the effective time into an option to purchase Strive Class A common stock, with the number of underlying Strive shares determined by the same 21.05 exchange ratio and the exercise price adjusted by dividing the prior Semler exercise price by that ratio.
Semler Scientific CEO Douglas Murphy-Chutorian reported the conversion of his Semler equity in connection with the company’s merger into Strive, Inc. On
On the same date, multiple Semler stock options to purchase common stock, with exercise prices ranging from
Semler Scientific director Daniel S. Messina reported the disposition of 11,910 shares of common stock and multiple stock options on January 16, 2026, in connection with the closing of the company’s merger with Strive, Inc. At the merger’s effective time, each outstanding Semler share was converted into the right to receive 21.05 shares of Strive Class A common stock, plus cash in lieu of fractional shares, under the merger agreement. Messina’s outstanding Semler stock options were converted into options to purchase Strive Class A shares, with the number of underlying shares and exercise prices adjusted by the same 21.05 exchange ratio, and any unvested portions of those options fully vested at the effective time.